Brief: Kelun-Biotech And Crescent Biopharma Announce Strategic Partnership
04/12/2025 13:39
Dec 4 (Reuters) - KELUN-BIOTECH AND CRESCENT BIOPHARMA ANNOUNCE STRATEGIC PARTNERSHIP TO DEVELOP AND COMMERCIALIZE NOVEL ONCOLOGY THERAPEUTICS CRESCENT BIOPHARMA INC - CR-001 AND SKB105 TO ENTER PHASE 1/2 TRIALS IN Q1 2026 CRESCENT BIOPHARMA INC - KELUN-BIOTECH TO RECEIVE $80 MILLION UPFRONT PAYMENT,ADDITIONAL MILESTONES OF UP TO US$1.25 BILLION FROM CRESCENT CRESCENT BIOPHARMA INC - CO TO RECEIVE $20 MILLION UPFRONT PAYMENT,ADDITIONAL MILESTONES OF UP TO US$30 MILLION FROM KELUN-BIOTECH CRESCENT BIOPHARMA INC - KELUN-BIOTECH ELIGIBLE FOR MILESTONES UP TO $1.25 BILLION Source text: ID:nGNXc0Mj7V ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering